Drug Information

Drug (ID: DG01772) and It's Reported Resistant Information

• Name: Hydrogen peroxide
• Synonyms: Hydrogen peroxide; 7722-84-1; perhydrol; oxydol; Hydrogen dioxide; hydroperoxide; Superoxol; Interox; Inhibine; Peroxaan; Peroxide; Albone; Hioxyl; Kastone; Albone 35; Albone DS; Dihydrogen dioxide; T-Stuff; Lensept; Elawox; Perone; Albone 50; Albone 70; Perone 50; Albone 35CG; Albone 50CG; Albone 70CG; Hydrogen peroxide solution; H2O2; Hydrogen peroxide (H2O2); Peroxan; Hydrogen peroxide, 30%; Hydrogen dioxide solution; Hydrogen peroxide, 90%; Perone 30; Perone 35; Hydrogen peroxide, solution; Waterstofperoxyde; Hydrogen peroxide, 3%; Wasserstoffperoxid; Caswell No. 486AAA; Peroxyde d'hydrogene; Perossido di idrogeno; Asepticper; Baquashock; Crystacide; Peroxclean; CCRIS 1060; Dentasept; HSDB 547; Hybrite; Metrokur; Mirasept; Oxigenal; Oxyfull; Oxysept; Pegasyl; Hipox; Select Bleach; Hydrogen peroxide, solution, 3%; Hydrogen peroxide solution (DOT); Xtra White; Hydrogen peroxide (conc > 52%); Oxysept I; Hydrogen peroxide solutions; Hydrogen peroxide, solution, 30%; Hydrogen peroxide, solution, 35%; Lensan A; Odosat D; UNII-BBX060AN9V; Adeka Super EL; Crestal Whitestrips; UN2014; UN2015; UN2984; EPA Pesticide Chemical Code 000595; Anti-Keim 50; Hydrogen peroxide, 8% to 20%; Hydrogen peroxide, 20% to 60%; Hydrogen peroxide (> 52% conc.); Hydrogen peroxide [USP]; MFCD00011333; UN 2015 (>52%); BBX060AN9V; UN 2984 (8%-20%); UN 2014 (20%-52%); CHEBI:16240; NSC-19892; Hydrogen peroxide solutions (over 8% but not over 60%); Hydrogen peroxide solutions (over 60% but not over 70%); Hydrogen peroxide (USP); PEO; dioxidane; Puresept; hydrogenperoxide; Waterstofperoxyde [Dutch]; Accel Concentrate; Wasserstoffperoxid [German]; Astri-UC; HTP [peroxide]; High Test Peroxide; CIX; Peroxyde d'hydrogene [French]; Teat dip HP 5; Perossido di idrogeno [Italian]; Pre milk HP 0.5; Pre milk HP 1.0; Hydrogen peroxide 35%; EINECS 231-765-0; NSC 19892; Pre milk HP 0.5 10; Whitespeed; Eskata; Magic Bleaching; Clarigel Gold; Hyrogen peroxide; Lase Peroxide; Quasar Brite; Opalescence Xtra; Whiteness HP; Deslime LP; Hydrogen peroxide (conc >52%); hydrogen per oxide; dihydrogen peroxide; dihydrogen(peroxide); Oxyfull (TN); HOOH; hydrogen hydroperoxide; Nite White Excel 2; Oxydol (JP17); Hydrogen peroxide 50%; HYDROGEN-PEROXIDE; Hydrogen peroxide aqueous; Hydrogen Peroxide, 50%; Hydrogen peroxide (8CI); MolMap_000025; bis(hydridooxygen)(O--O); EC 231-765-0; 30 %Hydrogen peroxide(aq); CHEMBL71595; Hydrogen peroxide 32 wt. %; OXTERIL 350 SPRAY; [OH(OH)]; DTXSID2020715; Hydrogen peroxide, 6% in water; Hydrogen peroxide (H2O2) (9CI); NSC19892; WLN: H2 O2 90%; Hydrogen Peroxide [Topical Solution]; AKOS015856794; DB11091; QTL1_000041; Hydrogen peroxide, aqueous solutions with >40% but not >60% hydrogen peroxide (stabilized as necessary) [UN2014] [Oxidizer]; Hydrogen peroxide, aqueous solutions with not <20% but not >40% hydrogen peroxide (stabilized as necessary) [UN2014] [Oxidizer]; Hydrogen peroxide, aqueous solutions with not <8% but <20% hydrogen peroxide (stabilized as necessary) [UN2984] [Oxidizer]; Hydrogen peroxide, stabilized or hydrogen peroxide aqueous solutions, stabilized with >60% hydrogen peroxide [UN2015] [Oxidizer]; FT-0627133; H1222; C00027; D00008; Hydrogen peroxide solution, 3%, for microbiology; Hydrogen peroxide solution, for ultratrace analysis; Q171877; Q1088474; Hydrogen peroxide solution, extra pure, 30.0-32.0%; Hydrogen peroxide solution, purum p.a., >=30% (RT); Hydrogen peroxide solution, purum p.a., >=35% (RT); Hydrogen peroxide solution, >=30%, for trace analysis; Hydrogen peroxide solution, SAJ first grade, >=30.0%; Hydrogen peroxide solution, tested according to Ph.Eur.; Hydrogen peroxide solution, 50 wt. % in H2O, stabilized; Hydrogen peroxide solution, JIS special grade, 30.0-35.5%; Hydrogen peroxide solution, 30 % (w/w) in H2O, contains stabilizer; Hydrogen peroxide solution, contains inhibitor, 35 wt. % in H2O; Hydrogen peroxide solution, p.a., ACS reagent, reag. ISO, 30.0%; Hydrogen peroxide 30%, meets the analytical specifications of Ph. Eur., stabilized; Hydrogen Peroxide Solution, 30% (w/w), puriss. p.a., reag. ISO, reag. Ph. Eur.; Hydrogen peroxide solution, AR, contains sodium pyrophosphate as stabilizer, >=30 % (w/v); Hydrogen peroxide solution, contains ~200 ppm acetanilide as stabilizer, 3 wt. % in H2O; Hydrogen peroxide solution, contains inhibitor, 30 wt. % in H2O, ACS reagent; Hydrogen peroxide solution, LR, contains sodium pyrophosphate as stabilizer, >=30 % (w/v); Hydrogen peroxide solution, LR, contains sodium pyrophosphate as stabilizer, >=50 % (w/v); Hydrogen peroxide solution, meets analytical specification of Ph. Nord., 34.5-36.5%; Hydrogen peroxide solution, puriss. p.a., ACS reagent, not stabilized, >=30% (RT); Hydrogen peroxide solution, semiconductor grade MOS PURANAL(TM) (Honeywell 17937), >=30%; Hydrogen peroxide solution, semiconductor grade PURANAL(TM) (Honeywell 17948), >=30%; Hydrogen peroxide solution, semiconductor grade ULSI PURANAL(TM) (Honeywell 17024), >=30%; Hydrogen peroxide solution, semiconductor grade VLSI PURANAL(TM) (Honeywell 17606), >=30%; Hydrogen peroxide solution, contains inhibitor, 30 wt. % in H2O, meets USP testing specifications; Hydrogen peroxide solution, contains potassium stannate as inhibitor, 30-32 wt. % in water, semiconductor grade, 99.999% trace metals basis; Hydrogen peroxide, aqueous solutions with >40% but not >60% hydrogen peroxide (stabilized as necessary); Hydrogen peroxide, aqueous solutions with >40% but not >60% hydrogen peroxide (stabilized as necessary) [UN2014] [Oxidizer]; Hydrogen peroxide, aqueous solutions with not <20% but not >40% hydrogen peroxide (stabilized as necessary); Hydrogen peroxide, aqueous solutions with not <20% but not >40% hydrogen peroxide (stabilized as necessary) [UN2014] [Oxidizer]; Hydrogen peroxide, aqueous solutions with not <8% but <20% hydrogen peroxide (stabilized as necessary); Hydrogen peroxide, aqueous solutions with not <8% but <20% hydrogen peroxide (stabilized as necessary) [UN2984] [Oxidizer]; Hydrogen peroxide, stabilized or hydrogen peroxide aqueous solutions, stabilized with >60% hydrogen peroxide; Hydrogen peroxide, stabilized or hydrogen peroxide aqueous solutions, stabilized with >60% hydrogen peroxide [UN2015] [Oxidizer]
• Indication:
  In total 1 Indication(s)
  Infectious disease [ICD-11: 1A00-CA43]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Heart failure [ICD-11: BD10]; [2]
  Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (2 diseases)
  Ischemia/reperfusion injury [ICD-11: DB98]; [3]
  Myocardial infarction [ICD-11: BA41]; [1]
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (5 diseases)
  Cataract [ICD-11: 9B10]; [4]
  Heart failure [ICD-11: BD10]; [5]
  Myocardial ischemia [ICD-11: BA6Z]; [6]
  Neurotoxicity [ICD-11: NE61]; [7]
  Periodontal ligament injury [ICD-11: NA0D]; [8]
• Target: PTPN1 messenger RNA (PTPN1 mRNA); PTN1_HUMAN; [1]
• IsoSMILES: OO
• InChI: InChI=1S/H2O2/c1-2/h1-2H
• InChIKey: MHAJPDPJQMAIIY-UHFFFAOYSA-N
• PubChem CID: 784
• ChEBI ID: CHEBI:16240
• TTD Drug ID: D03IDU
• VARIDT ID: DR0832
• DrugBank ID: DB11091

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-09: Visual system diseases

Cataract [ICD-11: 9B10]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Long non-protein coding RNA (GPX3-AS) [4]

• Molecule Alteration: Down-regulation; Expression
• Resistant Disease: Age-related cataract [ICD-11: 9B10.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: HLECs; N.A.; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: qRT-PCR; Western bloting analysis; Immunofluorescence assay; FISH assay
• Experiment for Drug Resistance: CCK8 assay; Flow cytometry assay
• Mechanism Description: GPX3-AS downregulated the apoptosis of LECs via promoting GPX3 expression, implying a novel therapeutic target for ARCs.

ICD-11: Circulatory system diseases

Myocardial infarction [ICD-11: BA41]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Taurine up-regulated 1 (TUG1) [1]

• Molecule Alteration: Up-regulation; Interaction
• Resistant Disease: Myocardial infarction [ICD-11: BA41.0]
• Experimental Note: Discovered Using In-vivo Testing Model
• Cell Pathway Regulation: miR-9/KLF5 signaling pathway; Inhibition; hsa05206
• Experiment for Molecule Alteration: Luciferase assay; Knockdown assay; Overexpression assay
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: The long non-coding RNA TUG1-miR-9a-5p axis contributes to ischemic injuries by promoting cardiomyocyte apoptosis via targeting KLF5.

Myocardial ischemia [ICD-11: BA6Z]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: H19, imprinted maternally expressed transcript (H19) [6]

• Molecule Alteration: Up-regulation; Interaction
• Resistant Disease: Myocardial ischemia [ICD-11: BA6Z.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: H9C2 cells; Ovary; Cricetulus griseus (Chinese hamster); CVCL_A0TS
• In Vivo Model: Rat model of heart IP and I/R injury; Rattus norvegicus
• Experiment for Molecule Alteration: Knockdown assay; Overexpression assay; qRT-PCR; Western bloting analysis; RIP experiments assay
• Experiment for Drug Resistance: CCK8 assay; caspase-3 activity assay
• Mechanism Description: LncRNA H19 is involved in myocardial IP via increasing the stability of nucleolin protein and LncRNA H19 may represent a potential therapeutic target for the treatment of the myocardial injury.

Heart failure [ICD-11: BD10]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: myosin heavy chain associated RNA transcript (MHRT) [2]

• Molecule Alteration: Down-regulation; Expression
• Resistant Disease: Chronic heart failure [ICD-11: BD10.2]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: AC16 cells; Heart; Homo sapiens (Human); CVCL_4U18
• Experiment for Molecule Alteration: qRT-PCR; Overexpression assay
• Experiment for Drug Resistance: Flow cytometry assay
• Mechanism Description: Chronic heart failure patients with lower expression levels of LncRNA MHRT had worse survival conditions compared to patients with higher expression levels of LncRNA MHRT.

Key Molecule: Growth arrest associated LncRNA 1 (GASAL1) [5]

• Molecule Alteration: Down-regulation; Expression
• Resistant Disease: Chronic heart failure [ICD-11: BD10.2]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: AC16 cells; Heart; Homo sapiens (Human); CVCL_4U18
• Experiment for Molecule Alteration: ELISA assay; qRT-PCR; Western bloting analysis; Overexpression assay
• Experiment for Drug Resistance: Flow cytometry assay
• Mechanism Description: LncRNA GASL1 is downregulated in chronic heart failure and regulates cardiomyocyte apoptosis.

ICD-13: Digestive system diseases

Ischemia/reperfusion injury [ICD-11: DB98]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Long non-protein coding RNA (ACART) [3]

• Molecule Alteration: Down-regulation; Expression
• Resistant Disease: Ischemia/reperfusion injury [ICD-11: DB98.B]
• Experimental Note: Discovered Using In-vivo Testing Model
• Cell Pathway Regulation: PPAR-gama/Bcl-2 signaling pathway; Activation; hsa04933
• In Vitro Model: NMVCs; N.A.; .; N.A.
• In Vivo Model: C57BL/6 mice and neonatal mice model of I/R injury model; Mus musculus
• Experiment for Molecule Alteration: Knockdown assay; Overexpression assay
• Experiment for Drug Resistance: MTT assay; TUNEL assay; Lactate dehydrogenase assay
• Mechanism Description: LncRNA ACART protects cardiomyocytes from apoptosis by activating PPAR- gama /Bcl-2 pathway.

ICD-22: Injury/poisoning/certain external causes consequences

Periodontal ligament injury [ICD-11: NA0D]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Long non-protein coding RNA (JHDM1D-AS1) [8]

• Molecule Alteration: Down-regulation; Expression
• Resistant Disease: Periodontal ligament injury [ICD-11: NA0D.1]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: Periodontal ligament stem cells; N.A.; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: Mimic assay; Overexpression assay
• Experiment for Drug Resistance: MTT assay; Cellular ROS detection assay; Flow cytometry assay
• Mechanism Description: Upregulation of JHDM1D-AS1 protects PDLSCs from H2O2-induced apoptosis by decreasing DNAJC10 via phosphorylation of eIF2alpha.

Neurotoxicity [ICD-11: NE61]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Long non-protein coding RNA (LOC284930) [7]

• Molecule Alteration: Down-regulation; Expression
• Resistant Disease: Neurotoxicity [ICD-11: NE61.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: SH-SY5Y cells; Abdomen; Homo sapiens (Human); CVCL_0019
• Experiment for Molecule Alteration: Overexpression assay; Knockdown assay
• Experiment for Drug Resistance: CCK8 assay; LDH assay; Caspase-3 activity assay
• Mechanism Description: Lnc-EPIC1 downregulation mediates H2O2-induced neuronal cell death.

References

• Ref 1: The long non-coding RNA TUG1-miR-9a-5p axis contributes to ischemic injuries by promoting cardiomyocyte apoptosis via targeting KLF5Cell Death Dis. 2019 Dec 2;10(12):908. doi: 10.1038/s41419-019-2138-4.
• Ref 2: Circulating lncRNA MHRT predicts survival of patients with chronic heart failureJ Geriatr Cardiol. 2019 Nov;16(11):818-821. doi: 10.11909/j.issn.1671-5411.2019.11.006.
• Ref 3: LncRNA ACART protects cardiomyocytes from apoptosis by activating PPAR-Gamma/Bcl-2 pathwayJ Cell Mol Med. 2020 Jan;24(1):737-746. doi: 10.1111/jcmm.14781. Epub 2019 Nov 20.
• Ref 4: Long noncoding RNA glutathione peroxidase 3-antisense inhibits lens epithelial cell apoptosis by upregulating glutathione peroxidase 3 expression in age-related cataractMol Vis. 2019 Nov 14;25:734-744. eCollection 2019.
• Ref 5: LncRNA GASL1 is downregulated in chronic heart failure and regulates cardiomyocyte apoptosisCell Mol Biol Lett. 2019 Jun 13;24:41. doi: 10.1186/s11658-019-0165-x. eCollection 2019.
• Ref 6: Downregulation of lncRNA H19 sensitizes melanoma cells to cisplatin by regulating the miR-18b/IGF1 axisAnticancer Drugs. 2020 Jun;31(5):473-482. doi: 10.1097/CAD.0000000000000888.
• Ref 7: LncRNA EPIC1 downregulation mediates hydrogen peroxide-induced neuronal cell injuryAging (Albany NY). 2019 Dec 8;11(23):11463-11473. doi: 10.18632/aging.102545. Epub 2019 Dec 8.
• Ref 8: Upregulation of JHDM1D-AS1 protects PDLSCs from H(2)O(2)-induced apoptosis by decreasing DNAJC10 via phosphorylation of eIF2AlphaBiochimie. 2019 Oct;165:48-56. doi: 10.1016/j.biochi.2019.06.018. Epub 2019 Jul 2.